Previously, therapeutic potential for FGF19 in the treatment of obesity and diabetes has been proposed [3], [4]; however, its promotion of hepatocyte proliferation and carcinogenic potential challenges the development of FGF19 for chronic use [15]. This evidence concerns the gene FGF19 and obesity due to melanocortin 4 receptor deficiency.